Comments to FDA: Transdermal and Topical Delivery Systems

Share page:

Comments | Feb 19, 2020

Docket Number:

Enclosed herein are comments on “Transdermal and Topical Delivery Systems - Product Development and Quality Considerations”. CHPA and our member companies marketing external analgesic ingredients have an interest, experience, and expertise in this area and appreciate this opportunity to comment.